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Summary 
Enforced expression of p210bcr-abl transforms interleukin 3 (IL-3)-dependent hematopoietic cell 
lines to growth factor-independent proliferation.  It has been demonstrated that nonreceptor tyrosine 
kinase oncogenes may couple to the p21ras pathway to exert their transforming effect. In particular, 
p210bcr-abl was recently found to effect p21ras activation in hematopoietic cells. In this context, 
experiments were performed to evaluate a protein signaling pathway by which p210bcr-abl might 
regulate p21ras. It was asked whether Shc p46/p52, a protein containing a src-homology region 
2 (SH2) domain, and known to function upstream from p21ras, might form specific complexes 
with p210bcr-abl and thus, possibly alter p21ras activity by coupling to the guanine nucleotide 
exchange factor (Sos/CDC25) through the Grb2 protein-Sos complex. This latter complex has 
been previously demonstrated to occur ubiquitously. We found that p210bcr-abl  formed a specific 
complex with Shc and with Grb2 in three different murine cell lines transfected with a p210bcr- 
abl expression vector. There appeared to be a higher order complex containing Shc, Grb2, and 
bcr-abl proteins. In contrast to p210bcr-abl transformed cells, in which there was constitutive 
tight  association  between  Grb2  and  Shc,  binding  between  Grb2  and  Shc was  Steel  factor 
(SLF)-dependent in a SLF-responsive,  nontransformed parental cell line.  The SLF-dependent 
association between Grb2 and Shc in nontransformed cells involved formation of a complex of 
Grb2  with  c-kit  receptor after SLF  treatment.  Thus,  p210bcr-abl  appears  to  function in  a 
hematopoietic p21ras activation pathway to allow growth factor-independent coupling between 
Grb2, which exists in a complex with the guanine nucleotide exchange factor (Sos), and p21ras. 
Shc may not be required for Grb2-c-kit  interaction, because it fails to bind strongly to c-kit. 
C 
hronic myelogenous leukemia (CML) 1 is a malignancy 
of pluripotential hematopoietic stem cells that is charac- 
terized cytogenetically by the presence of the Philadelphia 
chromosome (Ph  1) (1, 2).  This Ph  I translocation results in 
the head-to-tail fusion of 5' exons of the breakpoint cluster 
region (BCR)  gene on chromosome 22 with the abl gene 
on chromosome 9 (3).  This hybrid gene codes for a fusion 
protein (p210bcr-abl)  with a dysregulated tyrosine kinase ac- 
tivity (4, 5). p210bcr-abl has been shown to transform lym- 
phoid cells  (6),  to  transform IL-3-dependent cell lines to 
1 Abbreviations used in this paper: BCR, breakpoint cluster region; SH2, 
src-homology  region 2; SLF, Steel factor; Sos, son of sevenless. 
growth factor-independent proliferation (7), to cause various 
hematopoietic neoplasms including human CML-like syn- 
drome in mice (8, 9), and to lead to clonal heterogeneity in 
vitro (10).  Thus, p210bcr-abl has been linked as a decisive 
inciting factor in the pathogenesis of CML. Therefore, de- 
termining the intracellular pathways p210bcr-abl uses to confer 
these phenotypes is of significant interest. 
Discovery of a mutant H-ras with preferential affinity for 
GDP made possible  a significant advance in understanding 
how ras proteins participate in mitogenic signaling (11). When 
expressed in mammalian cells stimulated to proliferate by ac- 
tivation ofa tyrosine kinase receptor or by a nonreceptor tyro- 
sine kinase oncogene, this mutant ras protein blocked trans- 
mission of tyrosine kinase proliferative signals  (12, 13). We 
recently observed that the nonreceptor tyrosine kinase on- 
cogene p210bcr-abl effects a high state of activation in the 
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cells, p21ras activation, evidenced by GTP loading, was regu- 
lated by the tyrosine kinase activity of p210bcr-abl in the ab- 
sence of guanine  nucleotide pool changes  (14). 
It appears p210bcr-abl may activate p21ras by a mechanism 
facilitating guanine nucleotide exchange (e.g., by increasing 
the off-rate of GDP), based on estimates of guanine nucleo- 
tide pool size (intracellular ratios of GTP/GDP) and kinetics 
(15).  This concept is consistent  with  the observation that 
the dominant negative inhibitory ras mutant (Asn17) reverses 
transformation of NIH3T3 cells caused by nonreceptor tyro- 
sine kinase oncogenes (13). Dominant negative (Asn17) H-ras 
competitively inhibits the guanine nucleotide exchange factor, 
GDP dissociation stimulator (GDS), CDC25/Son of seven- 
less (Sos), in mitogenic signaling  (16).  Further,  the lack of 
binding by p120 rasGAP to GDP-bound p21ras makes rasGAP 
an unlikely candidate for the upstream component targeted 
by dominant  negative ras  (15). 
In this regard,  the information provided by introducing 
dominant  negative ras  into cells  complements  those gene- 
tic  studies  performed  in  Drosophila  and  in  the  nematode 
Caenorhabdtis elegans,  which place ras proteins downstream 
from tyrosine kinase receptors that are important  for devel- 
opment (17-19). Coupling between tyrosine kinase receptors 
and p21ras  has been linked,  first,  by these genetic studies, 
and more recently, by direct biochemical testing to Sem5/Grb2 
(20-26).  Grb2 contains a src-homology region 2 (SH2) do- 
main that  binds phosphotyrosine residue(s)  of tyrosine ki- 
nase receptors (20), and two SH3 domains that are now known 
to bind to a proline-rich motif of the guanine nucleotide ex- 
change factor Sos/CDC25 (21-23,  25, 26). The association 
between tyrosine kinase receptor and Grb2 was dependent 
upon ligand-activated  tyrosine autophosphorylation  of the 
receptor, whereas complex formation between Grb2 and Sos 
is independent  of external  signals  (22). 
Recently, a novel transforming protein called Shc, which 
contains a SH2 domain was cloned.  By structural  analysis, 
this protein lacks obvious catalytic domains to account for 
its transforming ability in NIH3T3 cells (27). Evidence exists 
functionally linking  Shc to the ras  signaling  pathway (27, 
28).  Although  Shc proteins  are heavily phosphorylated  on 
tyrosine in rat-2  cells  transformed  by v-src or v-fps,  there 
is no evidence that Shc associates with these nonreceptor tyro- 
sine kinases (29). On the other hand, Shc and Grb2 have been 
shown to bind directly to certain activated, autophosphorylated 
tyrosine kinase receptors with their SH2 domain (20, 27, 28). 
In addition, when Shc proteins are tyrosine phosphorylated, 
they bind with Grb2, which constitutively complexes with 
the guanine  nudeotide  exchange factor (Sos)  (21,  23). 
In this study, we examined how p210bcr-abl may lead to 
p21ras  activation,  and found evidence for a tight  complex 
formed constitutively between p210bcr-abl,  Shc,  and Grb2 
in p210bcr-abl transformed cells.  In contrast,  in a parental 
cell line lacking p210bcroabl,  but expressing the c-kit receptor, 
the association of Shc and Grb2 was dependent  upon steel 
factor (SLF) stimulation.  SLF triggered binding of Grb2 to 
tyrosine phosphorylated  c-kit. 
Materials and Methods 
Cytokines and Antibodies.  Highly purified recombinant murine 
steel factor (SLF) was a gift from Dr. Douglas E. Williams (Im- 
munex Corp.,  Seattle, WA). Rat anti-c-kit mAb, ACK-2, which 
recognizes the extraceUular domain of murine c-kit, was obtained 
from Gibco BRL (Gaithersburg,  MD). Affinity-purified anti-Shc 
Ab (raised against a 10-12-kD protein fragment of Shc), anti-Shc 
mAb (SC73), affinity-purified anti-Grb2 Ab (raised against the en- 
tire 24-kD protein from rat brain), anti-Grb2 mAb (GR81), and 
r-antiphosphotyrosine  Ab (RC20), were obtained from Transduc- 
tion Laboratories (Lexington,  KY).  Mouse antiphosphotyrosine 
mAb (4G10) was obtained from Upstate Biotechnology, Inc. (Lake 
Placid, NY). Anti-ABL mAb (24-21) and polyclonal anti-BCR an- 
tibody were purchased from Oncogene Science, Inc. (Uniondale, 
NY). 
Cells and Cell Culture.  The 32DC13 cell line was obtained from 
Joel Greenberger  (University  of Massachusetts Medical Center, 
Worcester, MA). The NSF/N1.H7 cell line and the MMTVras.G5 
cell lines have been described elsewhere (14, 30). The MMTVras.G5 
cell line was derived by placing nonadherent  bone marrow  cells 
into McCoy's 5A modified medium  (Gibco BRL) supplemented 
with  15% FCS and 10% WEHI-3 conditioned  medium  (a rich 
source of II.-3) plus SLF. These bone marrow cells were from the 
MMTV-v-H-ras transgenic oncomouse purchased from DuPont Co. 
(Wilmington, DE). Expression of the v-H-ras transgene was de- 
pendent upon the addition of dexamethasone. These cell lines were 
cultured  in McCoy's 5A modified supplemented with 15% FCS 
and 10% WEHI-3 conditioned  media. RmuSLF (50 ng/ml) was 
added for growth of the MMTVras.G5 cell line. K562 cell line sup- 
plied from the American Type Culture Collection (Rockville, MD) 
was cultured in RPMI 1640 supplemented with 10% FCS at 37~ 
5%  CO2.  For  experiments  including  factor  stimulation,  expo- 
nentially  growing  MMTVras.G5 cells and  transformed  derived 
MMTVras.bcr-ablG7 cells were washed and incubated for 18 h at 
37~  in serum-free McCoy's 5A modified medium containing 0.5% 
BSA (Sigma Chemical Co., St. Louis, MO). Then cells were washed 
once with serum-free medium  and exposed to growth factor. 
DNA  Transfection.  The plasmid vector pGD210 that contains 
p210bcr-abl cDNA was obtained from Drs. G. Daley and D. Balti- 
more (The Rockefeller University, New York [8]). pGD210 was 
linearized with Ndel (New England Biolabs, Beverly, MA) before 
electroporation.  Beginning 48 h after electroporation,  cells were 
selected with G418. Within 10 d of plating in the selection medium, 
G418-resistant sublines were obtained. 
Immunoblotting and Immunoprecipitation.  Immunoblotting was 
performed as previously described (31). Cells were lysed in 20 mM 
Tris-HC1, pH 7.4,  150 mM NaC1, 10% glycerol, 1% Triton X 
(Bio-Rad Laboratories, Richmond, CA) 1 mM PMSF, 0.15 U/ml 
aprotinin,  10/~g/ml leupeptin,  100 mM sodium fluoride, and 2 
mM sodium orthovanadate (Sigma Chemical Co.). Cell lysates at 
1 mg/100 #1 were mixed 1:1 with SDS sample buffer containing 
2-ME, boiled for 5 rain, and separated by SDS-PAGE. Proteins were 
transferred onto Immobilon  P membrane (Millipore Corp.,  Bed- 
ford, MA). Immunoblots were blocked in TBST (50 mM Tris-HC1, 
pH 7.4,  150 mM NaC1, 0.05% Tween 20) containing  1% BSA 
for 1 h. The blots were incubated with the appropriate primary 
Abs (antiphosphotyrosine  mAb (4G10), 1:1,000; r-antiphospho- 
tyrosine Ab (RC20), 1:2,500; anti-Shc mAb, 1:250; anti-Grb2mAb, 
1:250; anti-ABL mAb, 1:200  dilution) in TBST containing 1% BSA) 
for 2 h at room temperature.  Detection of the primary Ab was 
done with either one or two commercially available kits: (a) sec- 
ondary  Ab  conjugated  to  horseradish  peroxidase  (Amersham, 
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chemiluminescent  reaction  and exposed to radiographic film; or 
(b) secondary Ab conjugated to alkaline phosphatase (Zymed Labora- 
tories, Inc., S. San Francisco, CA) at  1:1,000 dilution  and devel- 
oped with substrate,  resulting  in a visible color reaction  on the 
membrane. Immunoprecipitations  were performed by incubating 
cell lysates with appropriate  Ab for 2 h at 4~  Anti-Shc,  anti- 
Grb2,  and anti-BCR immunoprecipitates  were collected by pro- 
tein A-Sepharose beads (Pharmacia, Uppsala, Sweden). Anti-ABL 
and  anti-c-kit  immunoprecipitates  were  collected  by  protein 
G-Sepharose beads (Oncogene Science, Inc.). The immunoprecipi- 
tates were washed four times gently with washing buffer (20 mM 
Tris-HC1, pH 7.4, 100 mM NaC1, 10% glycerol, 0.1% Triton X, 
100 mM sodium fluoride, and 2 mM sodium orthovanadate) be- 
fore analysis. 
Metabolic Labeling with [ssS]Methionine.  Growth factor-starved 
cells were washed and resuspended at 107 cells/ml in methionine- 
free medium with 150/xCi ml-1 [3SS]methionine (Amersham) for 
6 h.  Radiolabeled cells were stimulated  with growth factors and 
immediately lysed in lysis  buffer as described above. After removing 
insolved material by centrifugation,  cell lysates were used for im- 
munoprecipitation. 
Results 
Coimmunoprecipitation of  Shc Protein with p210bcr-abl in Three 
Different BCR-ABL  Transfected  Cell Lines.  The three different 
BCR-ABL transformed  cell lines,  bcr-ab132DC13,  H7bcr- 
ablA54,  and MMTVras.bcr-ablG7  were factor independent 
for proliferation (data not shown). When compared with the 
parental cell lines, BCR-ABL transformed cell lines exhibited 
prominent tyrosine phosphorylation of proteins as determined 
by antiphosphotyrosine  immunoblotting  (Fig.  1 A). These 
BCR-ABL transformed cell lines were also shown to express 
p210bcr-abl by anti-ABL  immunoblotting  after  anti-BCR 
immunoprecipitation  (Fig.  1 B). 
To analyze the interaction  of Shc with  other proteins in 
our cell lines,  it was first established that all cell lines equally 
expressed Shc p46/p52 proteins (Fig. 2 A). Because Shc pro- 
teins  possess a COOH-terminal  SH2 domain,  but  do  not 
possess any obvious catalytic domain (27), the possibility was 
considered that they might interact with other cytoplasmic 
signaling proteins. To test this hypothesis, the fate of Shc pro- 
teins in BCR-ABL transformed cells was examined.  Cells were 
lysed and incubated with anti-Shc Abs, and the precipitated 
proteins were analyzed by immunoblotting with antiphospho- 
tyrosine Abs (Fig.  2 B). Shc proteins  (p46Shc and p52Shc) 
were phosphorylated  on tyrosine in  the  BCR-ABL trans- 
formed cells compared with parental cell lines (Fig. 2 B). The 
background band around 50 kD is the Ig H  chain from the 
immunoprecipitation.  Since other proteins  phosphorylated 
on  tyrosine  including  Shc  itself  (approximate  molecular 
weights of 210,  154,  and  120) were coimmunoprecipitated 
with Shc proteins in the BCR-ABL, transformed cells,  we 
investigated the possibility that  p210bcr-abl was associated 
with Shc proteins. To test for complex formation, cell lysates 
were immunoprecipitated  with anti-Shc or control Abs fol- 
lowed by SDS-PAGE and immunoblotting with an anti-ABL 
Ab (Fig.  2 C).  The anti-Shc immune complexes contained 
Figure  1.  Expression  of p210bcr-abl  in three different  BCR-ABL  trans- 
fected cell lines. The parent cell lines are: 32DC13 (32D), NFS/N.1 H7 
(H7), MMTVras.G5 (G5). The pGD210 transformed cell lines are: bcr- 
ab132DC13 (32Dbcr-abl),  FI7bcr-abl  A54 (A54bcr-abl),  MMTVras.bcr-abl 
G7 (G7bcr-abl).  (A) Whole cell lysates  from each cell line were prepared 
and 50/zg of total protein analyzed  by 7.5% SDS-polyacrylamide  gel, im- 
munoblotted with antiphosphotyrosine  Ab (4G10). (B) Cell lysates  from 
the indicated  cell  lines were  immunoprecipitated (11))  with anti-BCP,, and 
immunoblotted (BLOT)  with anti-ABL mAb. Molecular  weight markers 
are in kilodaltons. 
the p210bcr-abl protein that reacted with anti-ABL Ab (Fig. 
2C). 
Because the anti-Shc Ab used in these studies was prepared 
against  a region  of Shc containing  an SH2 domain,  it was 
possible  that  the  anti-Shc  Ab  precipitated  p210bcr-abl  by 
reacting with an ABL SH2 domain. To further examine the 
possibility that Shc and p210bcr-abl could be specifically coim- 
munoprecipitated, cell lysates were immunoprecipitated with 
a specific anti-ABL Ab (directed against the unique COOH- 
terminal domain of ABL) and immunoblotted with anti-Shc 
(Fig. 2 D). Shc proteins were detected in anti-ABL immuno- 
precipitates from the BCR-ABL transformed cells, but not 
from  the parental  cell lines  (Fig.  2 D). 
Coimmunoprecipitation of Grb2 Proteins with p210bcr-abl in 
BCR-ABL  Transformed Cells.  It was first  established  that 
169  Tauchi  et al. Figure  2.  Formation  of a p210bcr-abl-Shc complex  in BCR-ABL transfected  cell lines. (A) Whole cell lysates  from each cell line were prepared, 
and 20/~g of total protein analyzed  by 7.5% SDS-polyacrylamide  gel, immunoblotted  with anti-Shc mAbs. (B) Cell lysates  from the indicated  cell 
lines were immunoprecipitated  (IP) with affinity-purified  anti-Shc or nonimmune  rabbit Ig Abs as a control (c, as noted for immunoprecipitation), 
and immunoblotted  (BLOT) with antiphosphotyrosine  Abs (RC20). The background  band around  50 kD is the Ig H chain  from the immunoprecipita- 
tion. (C) Affinity-purified  anti-Shc  or control  Ab immunoprecipitates  from the indicated  cell lines were probed with anti-ABL  mAbs. (D) The same 
lysates were immunoprecipitated  with anti-ABL  mAbs and immunoblotted  with anti-Shc. 
all cell lines equally expressed Grb2 proteins from whole cell 
lysates (Fig. 3 A). To determine whether Grb2 might associate 
with p210bcr-abl,  cell lysates in each cell line were immuno- 
precipitated  with  anti-Grb2  and  blotted  with  anti-ABL. 
p210bcr-abl  was detected in anti-Grb2 immunoprecipitates 
in the BCR-ABL transformed cell lines, but not parental cell 
lines (Fig.  3 B). Conversely, the cell lysates were immuno- 
precipitated with anti-ABL, and were immunoblotted with 
anti-Grb2. The anti-ABL immunocomplex contained Grb2 
protein in the BCR.-ABL transformed cell lines (Fig. 3 C). 
Formation of  a Shc-Grb2 Complex in BCR-ABL Transformed 
Cells.  To investigate the condition under which Shc pro- 
teins physically interact with Grb2, cell lysates from parent 
cells or BCR-ABL transformed 32DC13 cells were immu- 
noprecipitated with anti-Shc or anti-Grb2, and these immune 
complexes were then analyzed by immunoblotting with anti- 
Shc (Fig. 4, left), p46 Shc and p52 Shc could be readily de- 
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tected in anti-Grb2 immunoprecipitates from BCR-ABL trans- 
formed 32DC13 cells but not from parent 32DC13 cells. In 
a  similar experiment,  Grb2  was detected in  anti-Shc im- 
munoprecipitates  from BCR-ABL transformed 32DC13 cells 
(Fig.  4,  right). These results demonstrate that p210bcr-abl 
forms a single,  specific complex with Shc and Grb2. Identi- 
cal results, in which p210bcr-abl expression led to formation of 
complexes containing Shc-Grb2, were found with p210bcr-abl 
transformed clones, H7bcr-abl.A54,  and MMTVras. bcr-ablG7 
(data not shown). 
SLF Induces Tyrosine  Phosphorylation of  Shc in MMTVras.G5 
Cells.  Shc was previously shown to be phosphorylated on 
tyrosine residues in cells responding to epidermal growth factor 
(EGF), platelet-derived growth factor, and insulin (27, 32-34). 
Furthermore, activation of the EGF receptor has been shown 
to induce the formation of complexes  containing the au- 
tophosphorylated EGF receptor,  and Shc and Grb2 (29). We Figure  3.  Formation  of a p210bcr-abl-Grb2  complex  in BCR-ABL  trans- 
formed cell line. (A) Whole cell lysates from each cell line were analyzed 
by 10% SDS-polyacrylamide  gel, immunoblotted with anti-Grb2 mAb. 
(B) Affinity-purified  anti-Grb2 or nonimmune rabbit Ig immunoprecipi- 
tates from the indicated cell  lines were immunoblotted with anti-ABL  mAbs. 
(C) The same cell lysates  were immunoprecipitated with anti-ABL mAbs 
or control mouse Igs and immunoblotted with anti-Grb2 mAb. The back- 
ground bands around 50 and 27 kD are the Ig from immunoprecipitation. 
therefore investigated whether Shc and Grb2 were potential 
targets  of activated c-kit  receptor. 
In the factor-dependent  MMTVras.G5  parental  cell line, 
which expresses abundant c-kit receptors, stimulation of factor- 
starved cells with SLF led to an intense phosphotyrosine sub- 
strate band  at  52  kD,  putative  Shc  (Fig.  5).  The  substrate 
was most intensely tyrosine phosphorylated from 2 to 5 min 
after SLF  stimulation.  The cell lysates from MMTVras.G5 
cells  stimulated  with  SLF for 5  min were immunoprecipi- 
tated with anti-kit or anti-Shc Abs. The immunoprecipitates 
were resolved by 7.5%  SDS-PAGE  and  were visualized by 
immunoblotting  with  antiphosphotyrosine  (Fig.  6). 
Figure  4.  Coimmunoprecipitation  of Shc  and  Grb2  in 
BCIL-ABL transformed cell line. Cell lysates prepared from 
parental  32DC13 (32D) or  transformed  bcr-abl  32DC13 
(32Dbcr-abl) were imrnunoprecipitated with affinity-purified 
anti-Shc and anti-Grb2. The immunoprecipitates were sub- 
jected to immunoblot analysis with anti-Shc mAb and anti- 
Grb2 rnAb. 
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in MMTVras.G5 cells. MMTVras.G5  cells (107/ml) were stimulated  with 
SLF (50 ng/ml)  for the indicated  times. Cell  lysates  were  analyzed  by 7.5% 
SDS-PAGE and immunoblotted  with antiphosphotyrosine  (4G10). 
Immunoprecipitated c-kit protein was strongly tyrosine 
phosphorylated in response to SLF in MMTVras.G5  ceils, 
confirming the identity of the 145-160-kD phosphotyrosine 
substrate in whole cell lysates of SLF-stimulated cells (Fig. 
6 A, lanes 1 and 2).  In these lanes, it was apparent that the 
background bands at 52 kD were the Ig H chain from con- 
trol IgG immunoprecipitation (see below and Fig. 6/3, lane 
I-3).  Stimulation of MMTVras.G5 cells with SLF induced 
a prominent tyrosine phosphorylation of p46 Shc and p52 
Shc proteins revealed in the lysates immunoprecipitated with 
anti-Shc (Fig. 6 A, lanes 3 and 4). In anti-Shc immunoprecipi- 
tates,  SLF had also  induced tyrosine phosphorylation of a 
fainter 145-160-kD protein in MMTVras.G5 cells which cor- 
responds to the size of the immunoprecipitated c-kit receptor 
in these cells  (Fig.  6 A, lanes 3  and 4). 
To  determine  whether  Shc  might  associate  with  c-kit 
receptor, cell lysates from MMTVras.G5 cells stimulated with 
SLF were immunoprecipitated with anti-kit  or control rat 
IgG and then immunoblotted with anti-Shc Ab (Fig.  6/3, 
lanes  I-3).  Shc  could  not  be  detected  in  anti-kit  im- 
munoprecipitates upon SLF stimulation (Fig. 6 B, lanes 1-3). 
On the other hand, Shc proteins were detected from anti-ABL 
immunoprecipitates in bcr-abl transformed MMTVras.bcr- 
abl.G7 cells (Fig. 6 B, lanes 4-6).  As noted above, the ~52- 
kD band in the lanes containing lysates subjected  to anti-c- 
kit immunoprecipitation were not Shc, but rather Ig H chain 
(Fig.  6 A, lanes  I  and 2  vs.  Fig.  6 B, lanes  1-3). 
SLF Induces the Formation of a c-kit-Grb2  Complex in Pa- 
rental Cells. She Binds Stoichiometrically to Grb2 in Parental and 
p21Obcr-abl Transformed Cell Lines.  To obtain an overview 
of complexes  formed in parental MMTVras.G5 cells or in 
p210bcr-abl transformed MMTVras.bcr-ablG7 cells, these cells 
were metabolically labeled with [35S]methionine (Fig. 7 A). 
In part, this approach  was necessitated by the poor capacity 
of the c-kit Ab to recognize reduced and denatured c-kit on 
Western blots, whereas it functioned efficiently for immu- 
noprecipitation of native protein before reduction and denatu- 
ration (Figs.  6  and 7 A). 
MMTVras.G5 cells were deprived of growth factor and la- 
beled with  [3SS]methionine.  An  aliquot  was  subjected to 
stimulation with SLF, and the other half was unstimulated 
(Fig. 7 A). One portion of each group was immunoprecipi- 
tated with anti-Shc Abs, whereas the other was immunopre- 
cipitated with anti-c-kit or a nonimmune control serum (Fig. 
7 A). In the groups immunoprecipitated with anti-Shc,  the 
Shc p46/p52 bands were quantitatively unchanged upon SLF 
treatment (Fig.  7 A).  On the other hand, after SLF treat- 
ment, there was a quantitative increase in these anti-Shc im- 
munoprecipitates of 35S proteins corresponding to the p160 
band and p24 (Fig.  7 A). Subsequently, the same blot was 
immunoblotted with anti-Grb2. This 24-kD protein reacted 
with anti-Grb2 (Fig. 7 B). Conversely, when the lysates were 
immunoprecipitated with the anti-c-kit,  there was evidence 
of an increase of p24 Grb2 in the complexes of SLF-treated 
cells (Fig. 7 B). In the same condition, Shc could not be de- 
tected in anti-c-kit immunoprecipitates upon SLF treatment 
(Fig.  6 B, lanes  1-3). 
In contrast to dependence on SLF treatment for Grb2 coim- 
munoprecipitation with Shc in parental MMTVras.G5 cells, 
in p210bcr-abl  transformed derivative  MMTVras.bcr-ablG7 
Figure 6.  Tyrosine phosphorylation of c-kit and  Shc 
proteins in response to SLF. Shc proteins were not immuno- 
precipitated with c-kit. (A) MMTVras.G5 cells were treated 
with SLF for 5 min before cell lysis. Cell lysates were im- 
munoprecipitated  with anti-kit  or a~nity-purified  anti-Shc. 
Immunoprecipitates  were separated  by 7.5% SDS-PAGE  and 
immunoblotted with  antiphosphotyrosine (4G10). (B) 
MMTVras.G5  cells  and MMTV  ras. G7 cells  were  treated  with 
SLF for 5 min before  cell  lysis.  Cell  lysates  from  MMTVras.G5 
cells were  immunoprecipitated  with anti-kit  or control  rat IgG, 
and then immunoblotted  with anti-Shc  (lanes I-3). Cell  ly- 
sates from MMTV.ras.bcr-ablG7  cells were immunoprecipi- 
tated with anti-ABL  or control mouse  IgG, then immuno- 
blotted with anti-Shc (lanes 4-6). 
172  p210bcr-abl  Signal Transduction Figure  8.  SLF induces  formation  of  a Shc--Grb2  complex  in MMTVras.G5 
cells. MMTVras.G5  cells  were treated with SLF for 5 min before  cell  lysis. 
Cell lysates  were immunoprecipitated with affinity-purified  anti-Shc and 
anti-Grb2, then immunoblotted with anti-Shc mAb and anti-Grb2 mAb. 
Figure  7.  SLF-dependent  association  of Grb2 with c-kit in MMTVras.G5 
cells. (A) MMTVras.G5  cells and MMTVras.G7 cells were metabolically 
labeled with [3sS]methionine  for 6 h. After treatment with SLF for 5 min, 
the cell  lysates  were  immunoprecipitated  with anti-c-kit or ai~nity-purified 
anti-Shc or control rabbit Ig. Immunoprecipitates  were separated  by 10% 
SDS-PAGE and were visualized by autoradiography. (B) The same blot 
was immunoblotted with anti-Grb2 mAb. 
cells,  Grb2 was highly  associated with  Shc in  the  absence 
of SLF (Fig.  7, A  and B).  MMTVras.bcr-ablG7  cells  were 
found to possess c-kit receptors by immunofluorescence after 
labeling with biotin-conjugated SLF and fluoresceinated avidin, 
and by the same metabolic labeling procedure,  followed by 
c-kit  immunoprecipitation,  as  described  above  (data  not 
shown). However, the number of c-kit receptors were dimin- 
ished  compared  to  parental  cells. 
Finally,  we examined SLF-induced formation of Shc-Grb2 
complexes in MMTVras.G5 cells by developing duplicate blots 
with anti-Shc Ab or with the Grb2 Ab (Fig.  8). After SLF 
treatment, coimmunoprecipitation of one species (Shc or Grb2) 
with  the Ab against its binding  partner  was as efficient as 
direct immunoprecipitation  using self-specific  Abs (Fig.  8). 
This data argues for high affinity binding occurring between 
Grb2 and Shc after SLF treatment.  However, only Grb2 ap- 
pears to tightly complex c-kit upon SLF treatment  (Fig.  7). 
In control experiments, we addressed the possibility that Grb2 
might be tyrosine phosphorylated in its interaction with c-kit. 
We found no evidence for Grb2 tyrosine phosphorylation after 
SLF treatment  (data  not  shown). 
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Discussion 
A dominant negative inhibitory ras mutant (Asn17) reversed 
transformation  caused by nonreceptor  tyrosine  kinase  on- 
cogenes in fibroblasts (13). This observation suggested there 
might be a role for p21ras in hematopoietic signaling by the 
nonreceptor tyrosine kinase oncogene, p210bcr-abl.  In fact, 
it was recently shown that p210bcr-abl effects p21ras  activa- 
tion, evidenced by GTP loading, in hematopoietic cell lines 
transformed  by p210bcr-abl  (14). 
In constructing an hypothesis to understand how p210bcr- 
abl  might  couple  to  p21ras  activation,  we considered  the 
possible role of "adaptor" proteins  Shc and Grb2.  She was 
identified in fibroblasts as a transforming protein, whose struc- 
ture is lacking in obvious catalytic domains (27).  However, 
Shc is a tyrosine kinase substrate and itself contains an SH2 
domain capable of binding phosphotyrosine (27, 28). Shc can 
also induce PC12 pheochromocytoma cells  to differentiate. 
Shc induction of PC12 differentiation is blocked by the dom- 
inant negative (Ash17) ras, indicating that Shc functions up- 
stream  of p21ras  (29). 
Grb2 is another  structurally  simple adaptor protein  that 
consists entirely of an SH2 domain  and two SH3 domains 
(20). It is not a tyrosine kinase substrate and it binds avidly 
to autophosphorylated kinase receptors (20).  It has a proxi- 
mate  role  in  coupling  to  p21ras  activation  because of the 
binding of its SH3 domains to the p21ras guanine nucleotide 
exchange factor, Sos (20-23,  25, 26).  This binding interac- 
tion is independent  of external signals (22).  In contrast,  as- 
sociation of Grb2 with Shc only occurs when Shc has been 
tyrosine phosphorylated  (29,  34). 
In this study, we compared the coupling of these adaptor 
proteins, Shc and Grb2, with p210bcr-abl vs. c-kit.  We per- 
formed this study to gain understanding  of the different re- 
quirements  for coupling with the p21ras  pathway by these 
different  classes  of tyrosine  kinase  hematopoietic  effectors 
(receptors vs. nonreceptors). In factor-starved nontransformed 
parental MMTVrasG5  or 32DC13 cells,  Shc and Grb2 pro- 
teins were not associated (Figs.  4, 7, and 8). However upon 
treatment of the SLF-dependent cell line MMTVras.G5 with 
SLF, strong association between Shc and Grb2 occurred (Figs. 
7 and 8). This association was of such an affinity that stoichio- 
metric recovery of either species could be achieved by immu- noprecipitation of cell lysates with an Ab against its partner 
or against self (Fig.  8). This was determined by developing 
duplicate Western blots with Abs against Shc or Grb2 (Fig. 8). 
On the other hand, in three different p210bcr-abl trans- 
formed cells, Grb2 and Shc were constitutively associated in 
serum-starved cells lacking specific growth factors (IL-3  or 
SLF) (Figs.  4 and 7).  In these cells expressing p210bcr-abl, 
Shc proteins were heavily tyrosine phosphorylated (Fig. 2 B). 
The constitutive tight association of Shc and Grb2 in p210bcr- 
abl transformed cells involved the presence of p210bcr-abl in 
the same complex (Fig.  2, C and D, and Fig.  3, B and C). 
Within this complex, it therefore would appear Shc is a di- 
rect substrate of p210bcr-abl.  In such a model, Shc may act 
as a "bridge" or "spacer" for coupling p210bcr-abl  to the gua- 
nine nucleotide exchange factor (Sos) through Grb2. How- 
ever, it is also possible that Grb2 will bind directly to tyro- 
sine phosphorylated p210bcr-abl.  Further experiments are 
required to determine whether direct or indirect (via Shc) 
binding of Grb2-Sos to p210bcr-abl may be preferred for ras 
activation. 
Although several biochemical arguments favor the possi- 
bility that coupling of tyrosine kinases to p21ras activation 
should involve enhanced guanine nucleotide exchange rate, 
our data provide a physical link by which such a process could 
be facilitated. However, our data do not rule out the possible 
additional involvement of p210rasGAP in upstream regula- 
tion of p21ras by p210bcr-abl. Druker et al. (35) previously 
demonstrated that pl20rasGAP exists in a tight complex with 
p210bcr-abl. Maintenance of the GTP bound state of p21ras 
may involve the peculiar spacing within these complexes or 
an allosteric conformation of pl20rasGAP,  so that rasGAP 
might be unavailable to catalyze GTP hydrolysis on p21ras. 
It has been demonstrated that tyrosine phosphorylation of 
p120rasGAP does not alone negatively affect p21ras activity 
(36, 37). Both features of this model (involvement of Grb2- 
Sos and p120rasGAP)  would require proximity of p210bcr- 
abl-Grb2-Sos to the integral membrane ras protein. The ca- 
pacity for F-actin binding may provide for that function in 
p210bcr-abl  in the absence of a myristoylation motif that 
characterizes v-abI (38). 
In contrast to the high affinity interaction of both Shc and 
Grb2 with p210bcr-abl,  only Grb2 appeared to bind with 
high affinity with the activated c-kit receptor (Fig.  7).  We 
could not detect the direct association between activated c-kit 
receptor and Shc proteins (Fig. 7). Thus, even if Shc proteins 
directly associated with c-kit receptor, the association is very 
low affinity.  Alternatively, tyrosine phosphorylation of Shc 
might be an indirect step mediated by a nonreceptor tyrosine 
kinase that binds directly to c-kit.  Further work to unravel 
the features of c-kit signaling to p21ras  is warranted. 
In summary, this report provides an attractive explanation 
of the mechanism for p210bcr-abl  signaling in the p21ras 
pathway. By exerting its constitutive tyrosine kinase activity 
in a complex with Shc and Grb2,  it appears likely that an 
avenue is opened for coupling p210bcr-abl with a growth 
factor-independent p21ras  pathway via enhanced guanine 
nucleotide exchange. This pathway used by p210bcr-abl  ap- 
pears to differ from the similar pathway used by the tyrosine 
kinase receptor c-kit, both in terms of the requirements for 
specific ligand activation and in the signaling molecules that 
avidly bind to the tyrosine kinase effector. However, both 
p210bcr-abl  and activated c-kit have the capacity for inducing 
high affinity association between Grb2  and Shc. 
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